Enterin
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
518 Willow Ln, North Wales, Pennsylvania...Phone Number
(202) 444-6396Website
www.enterininc.comRevenue
$11.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Enterin
ENTERIN, INC focuses on Parkinson's research and aims to address the challenges posed by neurodegenerative diseases. The company is dedicated to improving patient outcomes through its findings and insights. Their intended clients include patients suffering from Parkinson's disease and healthcare professionals seeking innovative solutions. ENTERIN, INC is committed to advancing the understanding and treatment of neurodegenerative conditions.Explore more
Enterin Org Chart
OS
Clinical Research Associate
MG
Techniker
FC
Accounts Payable Specialist
HW
Senior Regulatory Advisor
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Enterin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Enterin, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Enterin launches new products
Check if Enterin has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Enterin is spiking on competitors!
Funding: Get notified immidiatlly once Enterin has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Enterin
Earning: See what the market has to say on Enterin recently announced quarterly report
Click to see if Enterin had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Enterin
Compare insights from companies similar to Enterin, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Enterin is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Enterin is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Enterin.
Enterin financials insights
Gather financial insights about Enterin, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$12.7M
2020
Debt
$150K
2021
Debt
$293K
Enterin Tech Stack
A closer look at the technologies used by Enterin
Most Recent Scoops
Executive Move
Board of Directors
Left Company
Executive Move
Chris Min, Vice President & Head of Medical & Clinical Development, has recently left the company to join Longeveron as Chief Medical Officer.
New Hire
Executive Move
Executive Moves, New Hire
Funding
Enterin News & Media
Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse Model
Data presented at the American Diabetes Association 83rd Scientific Sessions Data presented at the American Diabetes Association 83rd Scientific SessionsEnterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced the start of a Phase 1a study in obesity and Type 2 diabetes (IND #155001).Enterin announces FDA acceptance of an investigator sponsored IND to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01
PHILADELPHIA, May 31, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, announces the acceptance by the U.S. Food and Drug Administration (FDA) of an investigator sponsored Investigational New Drug (IND) application (166532) to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01. Treatment will continue indefinitely or until significant adEnterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia
PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases announces a collaboration with the Parkinson’s Virtual Biotech, the drug development and discovery arm of Parkinson's UK. A new phase 2 trial will study the effects of ENT-01 on Parkinson’s Disease (PD)-associated dementia. In January 2022, Enterin announced statistically significant r
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Enterin
Sign Up For FreeTo access detailed company insights
ENTERIN, INC focuses on Parkinson's research and aims to address the challenges posed by neurodegenerative diseases. The company is dedicated to improving patient outcomes through its findings and insights. Their intended clients include patients suffering from Parkinson's disease and healthcare professionals seeking innovative solutions. ENTERIN,... Read More
